The global Ebola Vaccine Market is estimated to be valued at US$ 5.83 Bn in 2023 and is expected to exhibit a CAGR of 32.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The Ebola vaccine market comprises live and non-live attenuated vaccines that offer improved immunogenicity and safety against the Ebola virus disease. These vaccines provide long term immunity against different strains of the virus and aid in preventing outbreaks.
Market key trends:
The use of nanotechnology based vaccine platforms is witnessing high growth in the Ebola vaccine market. Nanoparticle based vaccines offer multiepitope immunogenicity by mimicking viral structures and stimulating both humoral and cellular immune responses. They can encapsulate antigens, target specific immune cells and release antigens in a controlled manner. For instance, GlaxoSmithKline's VSV-EBOV vaccine uses the vesicular stomatitis virus vector engineered to produce an Ebola virus protein to trigger an immune response. The vaccine demonstrated high efficacy levels during clinical trials.
Segment Analysis
The global Ebola vaccine market is segmented based on product type, strain type, and end user. By product type, the live-attenuated vaccine segment holds the largest share due to advantages such as easy administration, fewer doses required for immunization, and lifelong protection offered by the vaccine. By strain type, Zaire Ebola virus segment dominates as it causes largest number of cases and deaths during Ebola outbreaks. By end user, the hospitals and clinics segment is the major shareholder due to higher patient footfall and availability of vaccination facilities.
Key Takeaways
The global Ebola vaccine market size is expected to grow at a CAGR of 32% over the forecast period due to increasing prevalence of Ebola virus disease and development of novel vaccines.
By region, North America is expected to grow at the fastest pace owing to robust research activities for Ebola vaccines and availability of advanced healthcare facilities. Europe holds the second largest share due to presence of major players and government funding for innovation.
Key players operating in the Ebola vaccine market are Merck & Co.Inc, GlaxoSmithKline plc, Mapp Biopharmaceutical, Nanoviricides Inc., Bavarian Nordic, Chimerix, Biocomo, Geneone Life Sciences Inc, NewLink Genetics Corporation, Novavax Inc, Johnson & Johnson Private Limited, Arbutus Biopharma, Sarepta Therapeutics, Hemispherx Biopharma Inc, IMV Inc, Peptineo, Biocryst Pharmaceuticals Inc. Merck & Co.Inc dominates the market due to its ERVEBO vaccine approved for prevention of Ebola virus disease
Get more insights on this topic: https://www.newsstatix.com/ebola-vaccine-market-industry-insights-trendsebola-vaccine-market-2023-2030/
Global Ebola Vaccine Market The GMI Research expects the Ebola Vaccine Market to notice an augmentation in demand over the forecast period.
This is mainly due to the increased mortality rate, lack of efficient treatments, rising concentration on research activities to launch effective medicines, and favorable government norms.Request a FREE Sample of Ebola Vaccine Market.Introduction of the Ebola Vaccine Market Ebola Vaccine or Ebola hemorrhagic fever (EHF) are vaccines either accepted or in the development phase to reduce the chances of Ebola resulting from the Ebola virus.
Besides this, it leads to the hemorrhagic fever that causes internal or external bleeding.Ebola Vaccine MarketKey Players of Market:Mapp Biopharmaceutical Inc.Merck & Company, Inc.Novavax Inc.Sarepta Therapeutics Inc.Regeneron PharmaceuticalsGlaxoSmithKline plc.GeoVax Labs Inc., LtdEbola Vaccine Market DynamicsThe comprehensive research and development activities to introduce a streamlined and robust solution for Ebola disease is a factor proliferating the opportunities in the Ebola Vaccine Market.
For example, key players such as Serepata Therapeutics, NewLink Genetics Tekmira Pharmaceuticals, and Mapp Biopharmaceutical are stressing research activities to establish Ebola Vaccine.
On the other hand, insufficient reconciliation policies in emerging countries and inadequate consciousness will restrain the Ebola virus Vaccine market size.Virus strain Segment DriversIn accordance with the Virus strain, Chimpanzee adenovirus type 3-Zaire Ebola virus is projected to witness faster growth over the forecast period.
Moreover, according to the Ebola market research reports, aggravating R activities for anti-Ebola products are likely to propel market growth.Regional DriversOn the basis of regional coverage, North America is contemplated to dominate the market during the coming years.
